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According to the Australian Study of Low Prevalence Dis-
orders [1], a great majority of people with chronic and
severe mental illness such as schizophrenia have harsh
and unfulfilling lives: 75% are single, 30% live alone,
35% have no contact with relatives, 75% have no friend
and 85% are reliant on welfare benefits. In the year prior
to the study, 16% of them had attempted suicide, 18%
had been a victim of violence, 15% felt unsafe where they
lived, 13% needed police or legal assistance and 10% had
been arrested. Nevertheless, when asked about their qual-
ity of life 60% of these people reported that they were
mostly satisfied with their current level of independence
and 44% were mostly satisfied with their life as a whole in
the past year.
This somewhat paradoxical finding points toward a lim-
ited applicability of the concept and measurement of
quality of life in people living with chronic and severe
mental illness. In an attempt to resolve this paradox, we
have developed a novel concept of “continuity of life” and
defined it as an individual's ability continue with activi-
ties, plans and hopes in spite of an event or process such
as chronic and severe mental illness. The concept has been
accompanied by a new assessment instrument entitled the
Continuity of Life Interview (COLI), which covers twelve
domains including some that are typically missed by the
quality of life measurements (e.g. access to material pos-
sessions and fulfilment of civic duties and responsibili-
ties). The COLI assessment process focuses on the present
state and future plans of the respondents, rather then on
their past [2,3].
The COLI was extensively evaluated in several studies
spanning different types of patients, settings and cultures.
Patients understood the concept and its domains well and
often expressed the view that the COLI interview gave
them the opportunity to discuss aspects of their mental ill-
ness that are often disregarded during the treatment proc-
ess. The COLI proved to be a cross-culturally appropriate
and reliable tool with kappa coefficients of 0.845 and
0.451 for inter-rater and test-retest reliability, respectively.
Furthermore, it has proven to be a suitable alternative
and/or complement to most currently used quality of life
measures. The COLI is now available to all potentially
interested users and we hope that this presentation will
prompt further translation, evaluation and application of
this novel instrument.
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